Senzime マネジメント

マネジメント基準チェック /34

Senzimeの CEO はPhilip Sibergで、 May2023年に任命され、の在任期間は 1.5年です。の年間総報酬はSEK 4.61Mで、 55.2%給与と44.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.62%を直接所有しており、その価値は€ 350.32K 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と3.7年です。

主要情報

Philip Siberg

最高経営責任者

SEK 4.6m

報酬総額

CEO給与比率	55.2%
CEO在任期間	1.5yrs
CEOの所有権	0.6%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	3.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Senzime の収益と比較して、Philip Siberg の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-SEK 131m
Jun 30 2024	n/a	n/a	-SEK 130m
Mar 31 2024	n/a	n/a	-SEK 131m
Dec 31 2023	SEK 5m	SEK 3m	-SEK 134m
Sep 30 2023	n/a	n/a	-SEK 138m
Jun 30 2023	n/a	n/a	-SEK 137m
Mar 31 2023	n/a	n/a	-SEK 143m
Dec 31 2022	SEK 450k	n/a	-SEK 133m
Sep 30 2022	n/a	n/a	-SEK 114m
Jun 30 2022	n/a	n/a	-SEK 104m
Mar 31 2022	n/a	n/a	-SEK 86m
Dec 31 2021	SEK 400k	n/a	-SEK 82m
Sep 30 2021	n/a	n/a	-SEK 74m
Jun 30 2021	n/a	n/a	-SEK 66m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 100k	n/a	-SEK 47m
Sep 30 2020	n/a	n/a	-SEK 41m
Jun 30 2020	n/a	n/a	-SEK 36m
Mar 31 2020	n/a	n/a	-SEK 32m
Dec 31 2019	SEK 100k	n/a	-SEK 33m
Sep 30 2019	n/a	n/a	-SEK 34m
Jun 30 2019	n/a	n/a	-SEK 33m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 100k	n/a	-SEK 24m
Sep 30 2018	n/a	n/a	-SEK 19m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 13m
Dec 31 2017	SEK 131k	n/a	-SEK 13m

報酬と市場: Philipの総報酬 ($USD 417.82K ) は、 German市場 ($USD 471.14K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Philipの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Philip Siberg (51 yo)

1.5yrs

在職期間

SEK 4,614,088

報酬

Mr. Philip Siberg serves as the Chief Executive Officer of Stille Surgical, Inc. He serves as Chairman of the Board at Acarix AB (publ) since May 11, 2021. He was Co-Founder of Coala-Life Group AB (publ) a...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Philip Siberg	Chief Executive Officer	1.5yrs	SEK 4.61m	0.62% € 350.3k
Slavoljub Grujicic	Chief Financial Officer	2.8yrs	データなし	0.022% € 12.4k
Johanna Tulkki	Chief Operating Officer	4.8yrs	データなし	データなし
Fredrik Norrby	Chief Technology Officer	1.8yrs	データなし	データなし
Rianne Waninge	Application Scientist	no data	データなし	データなし
Paula Treutiger	Head of Communication & Investor Relations	2.8yrs	データなし	データなし
Anders Selin	Executive Vice President of Sales	5.2yrs	データなし	データなし
Michael Noble	Vice President Global Marketing	less than a year	データなし	データなし
Anders Jacobson	Chief Innovation Officer	8.8yrs	データなし	0.014% € 7.9k
Catrin Molund	Executive Vice President of Business Development	3.8yrs	SEK 163.00k	データなし
Johanna Faris	Head of Q/RA/S	less than a year	データなし	0.0014% € 776.6

2.8yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: 6YCの経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Per Wold-Olsen	Chairman of the Board	less than a year	データなし	0.56% € 316.0k
Goran Brorsson	Independent Director	1.5yrs	SEK 131.00k	0.090% € 50.4k
Adam Dahlberg	Vice Chairman of the Board	24.8yrs	SEK 350.00k	5.55% € 3.1m
Eva Walde	Independent Director	3.7yrs	SEK 210.00k	データなし
Sorin Brull	Chief Medical Officer	8.8yrs	SEK 1.31m	3.33% € 1.9m
Alfredo Abad-Gurumeta	Member of Scientific Advisory Board	no data	データなし	データなし
Bela Fulesdi	Member of Scientific Advisory Board	no data	データなし	データなし
Guy Cammu	Member of Scientific Advisory Board	no data	データなし	データなし
Hans Boer	Member of Scientific Advisory Board	no data	データなし	データなし
Claude Meistelman	Member of Scientific Advisory Board	no data	データなし	データなし
Jennifer Hunter	Member of Scientific Advisory Board	no data	データなし	データなし
Casper Claudius	Member of Scientific Advisory Board	no data	データなし	データなし

3.7yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: 6YCの取締役会は経験豊富であると考えられます ( 3.7年の平均在任期間)。

Senzime マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Chairman of the Board recently bought €106k worth of stock

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

Less than half of directors are independent

Recent updates

Chairman of the Board recently bought €106k worth of stock

New minor risk - Profitability

Third quarter 2024 earnings released: kr0.26 loss per share (vs kr0.33 loss in 3Q 2023)

Senzime AB (publ) to Report Q1, 2025 Results on May 07, 2025

Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024

Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 Conference

Second quarter 2024 earnings released

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

New minor risk - Profitability

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.74 loss in 3Q 2022)

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

No longer forecast to breakeven

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

No longer forecast to breakeven

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Less than half of directors are independent

Independent Chairman recently bought €66k worth of stock

Less than half of directors are independent

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Less than half of directors are independent

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Senzime AB (publ) Provides Earnings Guidance for 2025

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Less than half of directors are independent

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings released: kr0.33 loss per share (vs kr0.27 loss in 1Q 2021)

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34